| 2022 | A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma
| INTERNATIONAL JOURNAL OF CANCER |
| 2019 | A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer | GASTRIC CANCER |
| 2019 | A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION |
| 2001 | A phase I/IIa study on intra-articular injection of holmium-166-chitosan complex for the treatment of knee synovitis of rheumatoid arthritis | EUROPEAN JOURNAL OF NUCLEAR MEDICINE |
| 2012 | A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy | INVESTIGATIONAL NEW DRUGS |
| 2021 | A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer | CLINICAL CANCER RESEARCH |
| 2019 | A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs | Lung Cancer |
| 2022 | A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib + rucaparib in patients with metastatic castration-resistant prostate cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer | CLINICAL CANCER RESEARCH |
| 2023 | A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma
| ESMO OPEN |
| 2016 | A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer | MOLECULAR CANCER THERAPEUTICS |
| 2009 | A phase II feasibility study of weekly paclitaxel in heavily pretreated advanced gastric cancer patients with poor performance status | ONCOLOGY |
| 2014 | A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer | INVESTIGATIONAL NEW DRUGS |
| 2023 | A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer
| ESMO OPEN |
| 2021 | A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis
| ANNALS OF ONCOLOGY |
| 2010 | A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer. | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS |
| 2020 | A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer
| CANCER RESEARCH AND TREATMENT |
| 2008 | A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2005 | A Phase II Study of Capecitabine Combined with Gemcitabine in Patients with Advanced Gallbladder Carcinoma
| YONSEI MEDICAL JOURNAL |
| 2008 | A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
